What it sells
At-home molecular tests for Lyme disease and STIs.
Business model breakdown
Buyer: who owns the budget?
UnverifiedConsumers (at-home kits) and clinics/health systems; partners commissioning diagnostics.
Trigger: what makes them buy now?
Lyme symptoms and antibodies appear weeks or months after a tick bite, leaving the disease undiagnosed; a test usable right after a bite fills the gap.
Workflow: what inputs become what output?
Sample skin interstitial fluid at the bite site, run a single-step, single-temperature freeze-dried paper-based molecular assay in a single-use cassette, read a visual result in about 30 minutes.
Economics: what it saves and how it charges
Sells single-use diagnostic kits and custom diagnostic development; claims 98% accuracy vs PCR and 100% specificity, with tests prototyped in days.
Distribution: how it reaches customers
Waitlist for launch; Lyme disease early detection kits and CT/NG (chlamydia, gonorrhoea) tests offered.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| 2026-07-10 | — | €5M | — | news.google.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-13.